Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Page 1
Atelectasis and survival after bronchoscopic lung volume reduction for COPD.
Hopkinson NS, Kemp SV, Toma TP, Hansell DM, Geddes DM, Shah PL, Polkey MI. Hopkinson NS, et al. Among authors: geddes dm. Eur Respir J. 2011 Jun;37(6):1346-51. doi: 10.1183/09031936.00100110. Epub 2010 Oct 14. Eur Respir J. 2011. PMID: 20947683 Free article.
The benefit is most pronounced in, though not confined to, patients where lobar atelectasis has occurred. Few data exist on their long-term outcome. 19 patients (16 males; meansd forced expiratory volume in 1 s 28.411.9% predicted) underwent BLVR between July 2002 and Febr …
The benefit is most pronounced in, though not confined to, patients where lobar atelectasis has occurred. Few data exist on their long-te …
Poly (D, L-lactide-co-glycolide)/DNA microspheres to facilitate prolonged transgene expression in airway epithelium in vitro, ex vivo and in vivo.
Stern M, Ulrich K, Geddes DM, Alton EW. Stern M, et al. Among authors: geddes dm. Gene Ther. 2003 Aug;10(16):1282-8. doi: 10.1038/sj.gt.3301994. Gene Ther. 2003. PMID: 12883524
Repeat administration of gene therapy for cystic fibrosis is likely to be essential for long-term clinical efficacy. This may be minimized by the use of slow-release gene transfer preparations with more prolonged expression and longer dosing intervals for the patient. ...
Repeat administration of gene therapy for cystic fibrosis is likely to be essential for long-term clinical efficacy. This may be mini …
Bronchoscopic volume reduction with valve implants in patients with severe emphysema.
Toma TP, Hopkinson NS, Hillier J, Hansell DM, Morgan C, Goldstraw PG, Polkey MI, Geddes DM. Toma TP, et al. Among authors: geddes dm. Lancet. 2003 Mar 15;361(9361):931-3. doi: 10.1016/S0140-6736(03)12762-6. Lancet. 2003. PMID: 12648974
Lung-volume reduction can be achieved with unilateral bronchoscopically placed valve implants in patients with severe emphysema with acceptable short-term safety and worthwhile functional benefits....
Lung-volume reduction can be achieved with unilateral bronchoscopically placed valve implants in patients with severe emphysema with accepta …
Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis.
Ferrari S, Geddes DM, Alton EW. Ferrari S, et al. Among authors: geddes dm. Adv Drug Deliv Rev. 2002 Dec 5;54(11):1373-93. doi: 10.1016/s0169-409x(02)00145-x. Adv Drug Deliv Rev. 2002. PMID: 12458150 Free PMC article. Review.
In addition, once in the cell, further hurdles have to be overcome, including DNA degradation, nuclear import and the ability to maintain long-term transgene expression. Strategies to overcome these barriers will be addressed in this review and include the use of: (i) clin …
In addition, once in the cell, further hurdles have to be overcome, including DNA degradation, nuclear import and the ability to maintain lo …
Cyclosporin as an oral corticosteroid sparing agent in stable asthma.
Evans DJ, Cullinan P, Geddes DM. Evans DJ, et al. Among authors: geddes dm. Cochrane Database Syst Rev. 2001;2000(2):CD002993. doi: 10.1002/14651858.CD002993. Cochrane Database Syst Rev. 2001. PMID: 11406057 Free PMC article. Review.
BACKGROUND: Patients with chronic severe asthma are often dependent on the long term prescription of oral corticosteroids. The use of steroids is associated with serious side effects. ...
BACKGROUND: Patients with chronic severe asthma are often dependent on the long term prescription of oral corticosteroids. The use of …
Troleandomycin as an oral corticosteroid steroid sparing agent in stable asthma.
Evans DJ, Cullinan P, Geddes DM. Evans DJ, et al. Among authors: geddes dm. Cochrane Database Syst Rev. 2001;2000(2):CD002987. doi: 10.1002/14651858.CD002987. Cochrane Database Syst Rev. 2001. PMID: 11406054 Free PMC article. Review.
BACKGROUND: Patients with chronic severe asthma are often dependent on the long term prescription of oral corticosteroids. The use of steroids is associated with serious side effects. ...
BACKGROUND: Patients with chronic severe asthma are often dependent on the long term prescription of oral corticosteroids. The use of …
Gold as an oral corticosteroid sparing agent in stable asthma.
Evans DJ, Cullinan P, Geddes DM. Evans DJ, et al. Among authors: geddes dm. Cochrane Database Syst Rev. 2001;2000(2):CD002985. doi: 10.1002/14651858.CD002985. Cochrane Database Syst Rev. 2001. PMID: 11406053 Free PMC article. Review.
BACKGROUND: Patients with chronic severe asthma are often dependent on the long term prescription of oral corticosteroids. The use of steroids is associated with serious side effects. ...
BACKGROUND: Patients with chronic severe asthma are often dependent on the long term prescription of oral corticosteroids. The use of …
Experience of totally implantable venous access devices (TIV ADs) in adults with cystic fibrosis over a 13-year period.
Kariyawasam HH, Pepper JR, Hodson ME, Geddes DM. Kariyawasam HH, et al. Among authors: geddes dm. Respir Med. 2000 Dec;94(12):1161-5. doi: 10.1053/rmed.2000.0943. Respir Med. 2000. PMID: 11192950 Free article.
The group as a whole had fewer infectious complications than in most other reported series. We conclude that TIVADs provide effective and long-term intravenous access and have fewer complications if they are inserted and cared for at a centre with special expertise in thei …
The group as a whole had fewer infectious complications than in most other reported series. We conclude that TIVADs provide effective and lo …
Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis.
Shah PL, Scott SF, Geddes DM, Hodson ME. Shah PL, et al. Among authors: geddes dm. Respir Med. 1995 Aug;89(7):499-502. doi: 10.1016/0954-6111(95)90126-4. Respir Med. 1995. PMID: 7480980 Free article. Clinical Trial.
A cohort of 52 cystic fibrosis patients with a FVC > 40% predicted were enrolled into an open label study in order to evaluate longer-term effects of rhDNase. They received 2.5 mg rhDNase twice daily for 6 months followed by a 2-week wash-out period, and for the subsequ …
A cohort of 52 cystic fibrosis patients with a FVC > 40% predicted were enrolled into an open label study in order to evaluate longer- …
16 results